Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough Ascentage Pharma (6855.HK) announced today that it has released updated clinical results of olverembatinib (HQP1351), a third-generation tyrosine kinase inhibitor (TKI), in patients with TKI-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST), in Read More ›

SUZHOU, China, and ROCKVILLE, MD, June 5, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Clinical Advisory Board member Prof Hagop M. Kantarjian has received the David A. Karnofsky Memorial Award for his lifelong contributions to leukemia clinical Read More ›

Ascentage Pharma (6855.HK) announced today that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has recommended olverembatinib (HQP1351), Ascentage Pharma’s lead novel drug candidate, for a Breakthrough Therapy Designation (BTD) for the treatment of patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) who had received first-line treatment. This marks Read More ›

Ascentage Pharma (6855.HK)  announced today that 4 of its abstracts were selected for presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These studies report on four of the company’s lead drug candidates, including the first and only China-approved third-generation Bcr-Abl inhibitor, olverembatinib (HQP1351), Bcl-2 selective inhibitor, lisaftoclax (APG-2575), MDM2-p53 inhibitor, alrizomadlin Read More ›

Ascentage Pharma today announced that results from four clinical studies of the company’s key assets, including the first China-approved third-generation BCR-ABL tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351), Bcl-2 selective inhibitor lisaftoclax (APG-2575), MDM2-p53 inhibitor alrizomadlin (APG-115), and FAK/ALK/ROS1 inhibitor (APG-2449), have been selected for presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Read More ›

Ascentage Pharma (6855.HK) today announced that it recently received a zero-deficiency report from the GMP compliance audit of Ascentage Pharma’s Global Manufacturing Center by a Qualified Person (QP) of the European Union (EU). This successful audit indicates that the company’s Global Manufacturing Center and quality management system implemented at the site are now compliant with Read More ›

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it had released results from three preclinical studies of the company’s China-approved novel third-generation BCR-ABL inhibitor olverembatinib (HQP1351), and two key investigational apoptosis-targeted drug candidates of Ascentage Pharma, the Bcl-2 inhibitor Read More ›

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2022. During the reporting period, the company upheld the concept of original innovation and global innovation, and achieved multiple milestones in commercialization, clinical development, and Read More ›

Ascentage Pharma (6855.HK) today announced that the latest results from three preclinical studies of the company’s novel third-generation BCR-ABL inhibitor olverembatinib (HQP1351) and two key assets of Ascentage Pharma’s apoptosis-targeting pipeline, the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), have been selected for presentations at the 2023 American Association of Cancer Research Annual Meeting (AACR 2023). These Read More ›

Ascentage Pharma and Innovent Biologics today announced that the novel drug olverembatinib has been included into the China 2022 National Reimbursement Drug List（NRDL), for the treatment of T315I-mutant chronic-phase chronic myeloid leukemia (CML-CP) and accelerated-phase CML (CML-AP). The new version of the NRDL will take effect on Mar 1st, 2023. Developed by Ascentage Pharma with Read More ›